Circadian chemotherapy for gynecological and genitourinary cancers

REFERENCES

• Focan C. Rythme nychémélal de la Division Cellulaire et Chimiothérapie de Shynchronisation—Recrutement en CancÉRologie Cliniuqe. Rev. Med. Liège. 1975; 30: 461–466
   PubMedGoogle Scholar
• Klevecz R.R., Shymko R.M., Blumenfeld D., Braly P.S. Circadian Gating of S-Phase in Human Ovarian Cancer. Cancer Res. 1987; 47: 6267–6271
   PubMed Web of Science ®Google Scholar
• Hrushesky W.J.M., Lannin D., Haus E. Evidence for an Ontogenic Basis for Circadian Coordination of Cancer Cell Proliferation. J. Natl Cancer Inst. 1998; 90: 1480–1484
   PubMedGoogle Scholar
• Kuhl J.F.W., Grage F., Halberg F., Rosene G., Scheving L.E., Haus E. Ellen-Effect: Tolerance of Adriamycin by Bagg Albino Mice and Fisher Rats Depends on Circadian Timing of Injection. Int. J. Chronobiol. 1973; 1: 335–336
   Google Scholar
• Sothern R.B., Nelson W.L., Halberg F. A. Circadian Rhythm in Susceptibility of Mice to the Anti-Tumor Drug Adriamycin. Il Ponte, Milan 1977; 433–438
   Google Scholar
• Lévi F., Halberg F., Haus E., Sanchez de la Pena S., Sothern R., Halberg E., Hrushesky W.J.M., Brown H., Scheving L., Kennedy B.J. Synthetic Adrenocorticotropin for Optimizing Murine Circadian Chronotolerance for Adriamycin. Chronobiologia 1980; 7: 227–244
   PubMedGoogle Scholar
• Halberg E., Halberg F., Venner K.J., Scheving L.E., Cornelissen G., De Prins J., Hrushesky W.J.M., Kennedy B. Chronopharmacology, A. Reinberg, F. Halberg. Pergamon Press, New York 1979; 377, Twenty-Four Hour Synchronized Chronotolerance of cis-Diamminedichloroplatinum (II) by Rats on 8-h and 12-h Photofraction Gauged by Acrophase and Paraphase of Rectal Temperature
   Google Scholar
• Hrushesky W.J.M., Lévi F., Halberg F., Kennedy B. Circadian Stage Dependence of cis-Diamminedichloroplatinum Lethal Toxicity in Rats. Cancer Res. 1982; 42: 945–949
   PubMed Web of Science ®Google Scholar
• Boughattas A.N., Lévi F., Roulon A., Mechkouri M., Lemaigre G., Cal J., Cambar Reinberg A., Mathe G. Similar Circadian Rhythm in Murine Host Tolerance for Two Platinum Analogs: Carboplatin (cbdca) and Oxaliplatin (i-ohp). Proc. Annu. Meet Am. Assoc. Cancer Res. 1987; 28: 451, (abstr)
   Google Scholar
• Sothern R.B., Lévi F., Haus E., Halberg F., Hrushesky W.J.M. Control of a Murine Plasmacytoma with Doxorubicin–Cisplatin: Dependence on Circadian Stage of Treatment. J. Natl Cancer Inst. 1989; 81: 135–145
   PubMedGoogle Scholar
• Hrushesky W.J.M. Circadian Timing of Cancer Chemotherapy. Science 1985; 228: 73–75
   PubMed Web of Science ®Google Scholar
• Hrushesky W.J.M., von Roemeling R., Sothern B. Circadian Chronotherapy: From Animal Experiments to Human Cancer Chemotherapy. Chronopharmacology: Cellular and Biochemical Interactions, B. Lemmer. Marcel Dekker, Inc., New York 1989; 439–473
   Google Scholar
• Lévi F., Benavides M., Chevelle C., Le Saunier F., Bailleul F., Misset J.L., Regensberg C., Vannetzel J.M., Reinberg A., Mathé G. Chemotherapy of Advanced Ovarian Cancer with 4′-O-Tetrahydropyranyl Doxorubicin and Cisplatin: a Randomized Phase II Trial with an Evaluation of Circadian Timing and Dose-Intensity. J. Clin. Oncol. 1990; 8: 705–714
   PubMed Web of Science ®Google Scholar
• Lévi F., Mechkouri M., Roulon A., Bailleul F., Lemaigre G., Reinberg A., Mathé G. Circadian Rhythm in Tolerance of Mice for the New Anthracycline Analog 4′- Tetrahydropyranyladriamycin (THP). Eur. J. Cancer Clin. Oncol. 1985; 21: 1245–1251
   PubMedGoogle Scholar
• Lévi F., Blazsek I., Ferlé-Vidovic A. Circadian and Seasonal Rhythms in Murine Bone Marrow Colony-Forming Cells Affect Tolerance for the Anticancer Agent 4′-O-Tetrahydropyranyladriamycin (THP). Exp. Hematol. 1988; 16: 696–701
   PubMed Web of Science ®Google Scholar
• Barrett R.B., Blessing J.A., Homesley H.D., Twiggs L., Webster K. Circadian-Timed Combination Doxorubicin–Cisplatin Chemotherapy for Advanced Endometrial Carcinoma. Am. J. Clin. Oncol. 1993; 16: 494–496
   PubMed Web of Science ®Google Scholar
• Hrushesky W.J.M., von Roemeling R., Wood P.A., Langevin T.R., Lange P., Fraley E. High-Dose Intensity Systemic Therapy of Metastatic Bladder Cancer. J. Clin. Oncol. 1987; 5: 450–455
   PubMedGoogle Scholar
• Hrushesky W.J.M., von Roemeling R., Wood P.A., Langevin T.R., Lange P., Fraley E. High-Dose Intensity Circadian-Timed Doxorubicin and Cisplatin Adjuvant Chemotherapy for Bladder Cancer. Cancer Treat. Rep. 1987; 71: 915–919
   PubMedGoogle Scholar
• von Roemeling R., Hrushesky W.J.M. Determination of the Therapeutic Index of Floxuridine by Its Circadian Infusion Pattern. J. Natl Cancer Inst. 1990; 82: 386–393
   PubMedGoogle Scholar
• Hrushesky W.J.M., von Roemeling R., Lanning R.M., et al. Circadian-Shaped Infusion of Floxuridine for Progressive Metastatic Renal Cell Carcinoma. J. Clin. Oncol. 1990; 8: 1504–1513
   PubMed Web of Science ®Google Scholar
• Bjarnason G.A., Hrushesky W.J.M., Marsh R., Diasio R., Harris J., Huben R., Loch J.J., Dugan W., Anderson J. Flat Versus Time-Modified 14-Day Infusion of FUDR for Advanced Renal Cell Cancer: a Phase-III Study. Biol. Rhythm Res. 1995; 26: 369
   Google Scholar
• Rajagopalan K., Peereboom D., Budd G., Olencki T., Murthy S., Elson P., McLain D., Bukowski R. Phase II Trial of Circadian Infusion Floxuridine (FUDR) in Hormone Refractory Metastatic Prostate Cancer. Investig. New Drugs 1999; 16: 255–258
   Google Scholar
• Deprés-Brummer P., Lévi F., Di Palma M., Beliard A., Lebon P., Marion S., Jasmin C., Misset J.L. A Phase I Trial of 21-Day Continuous Venous Infusion of a-Interferon at Circadian Rhythm Modulated Rate in Cancer Patients. J. Immunother. 1991; 10: 440–447
   PubMedGoogle Scholar
• Iacobelli S., Garufi C., Itrelli L., Martino M.T., Santobuono F., Vicario G., Tinari N., Fiorentino B., Innocenti P., Natoli C. A Phase I Study of Recombinant Interferon-Alpha Administered as a Seven-Day Continuous Infusion at Circadian-Rhythm Modulated Rate in Patients with Cancer. Am. J. Clin. Oncol. 1995; 18: 27–31
   PubMedGoogle Scholar
• Bruguerolle B., Lévi F., Arnaud C., Bouvenout G., Mechkouri M., Vannetzel J.M., Touitou Y. Annual Review of Chronopharmacology, A. Reinberg, M. Smolensky, G. Labrecque. Pargamon Press, Oxford 1984; 3: 207–210, Alteration of Physiological Circadian Time Structure of Six Plasma Proteins in Patients with Advanced Cancer
   Google Scholar
• Touitou Y., Focan C. Rhythms in Tumor Markers. Biologic Rhythms in Clinical and Laboratory Medicine, Y. Touitou, E. Haus. Springer-Verlag, Berlin 1992; 647–648
   Google Scholar
• Damascelli B., Marchiano A., Spreafico C., Lutman R., Salvetti M., Bonalumi M.G., Mauri M., Garbagnati F., Del Nero A., Comeri G., Conti G., Coppoli S., Bennetti G., Tralongo P. Circadian Continuous Chemotherapy of Renal Cell Carcinoma with an Implantable, Programmable Infusion Pump. Cancer 1990; 66: 237–247
   PubMed Web of Science ®Google Scholar
• Huben R.P., Dragone N., Perrapato S.D. Continuous Infusion FUDR Chemotherapy in the Treatment of Metastatic Renal Cell Carcinoma. Am. Urol. Assoc. 1990; 413
   Google Scholar
• Dexeus F.H., Logothetis C.J., Sella A., Amato R., Kilbourn R., Ogden S., Striegel A., Kwan J., Newman R.A. Circadian Infusion of Floxuridine in Patients with Metastatic Renal Cell Carcinoma. J. Urol. 1991; 146: 709–713
   PubMed Web of Science ®Google Scholar
• Wilkinson M.J., Frye J.W., Small E.J., Venook A.P., Carroll P.R., Ernest M.L., Stagg R.J. A Phase II Study of Constant-Infusion Floxuridine for the Treatment of Metastatic Renal Cell Carcinoma. Cancer 1993; 71: 3601–3604
   PubMedGoogle Scholar
• Conroy T., Geoffrois L., Guillemin F., Luporsi E., Krakowski I., Spaeth D., Frasie V., Volff D. Simplified Chronomodulated Continuous Infusion of Floxuridine in Patients with Metastatic Renal Cell Carcinoma. Cancer 1993; 72: 2190–2197
   PubMed Web of Science ®Google Scholar
• Natoli C., Irtelli L., Martino M.T., Gallo-Stampino C., Criscuolo D., Santobuono F., Iacobelli S. A Phase II Evaluation of 5-Fluoro-2-deoxyuridine Administered as a 14-Day Continuous Venous Infusion at Circadian-Rhythm Modulated Rate in Gastrointestinal Cancer and Renal Cell Carcinoma. J. Infus. Chemother. 1994; 4: 97–99
   Google Scholar
• Sampaio C., Olencki T., Murthy S., Budd G.T., McLain D., Lorenzi V., Bukowski R.M. Phase II Trial of Circadian Infusion of the Antimetabolite Floxuridine in Patients with Metastatic Renal Cell Carcinoma. J. Infus. Chemother. 1994; 4: 100–103
   Google Scholar